Pharmamarketeer

Array melanoma drugs show significant survival vs Roche drug in study

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study.

Reageer

Medhc-fases-banner
Advertentie(s)